EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES (EEJBS)
ISSN: 2992-4138 **©EEJBS Publications**
Volume 6 Issue 2 2025

Effect of CRISPR-Cas9 Beta-Cell Editing versus Insulin Therapy on Glycemic Control in Type 1 Diabetic Adults: A Narrative Review

Kintuza Lumwako Tebulo

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency and hyperglycemia. While insulin therapy remains the cornerstone of management, it carries significant limitations, including glycemic variability, hypoglycemia risk, and lifelong treatment burden. CRISPR-Cas9 beta-cell editing has emerged as a novel intervention capable of regenerating functional beta cells and restoring endogenous insulin production. This narrative review compared the effectiveness of CRISPR-Cas9 beta-cell editing versus insulin therapy on glycemic control among type 1 diabetic adults. A comprehensive literature search was conducted using PubMed and Google Scholar databases, focusing on preclinical and early clinical studies exploring CRISPR-Cas9-mediated beta-cell editing for T1DM. Evidence suggested that gene-edited beta-like cells achieve near-normalization of blood glucose levels in animal models, with potential reductions in hypoglycemia risk and treatment burden compared to exogenous insulin. However, safety concerns such as off-target genomic effects, tumorigenicity, immune rejection, and ethical issues remain major translational barriers. Insulin therapy, despite its drawbacks, continues as the standard of care pending further clinical validation of gene-editing interventions. Future success will depend on addressing safety, regulatory, and ethical challenges to realize CRISPR-Cas9's transformative potential in T1DM management.

Keywords: Type 1 Diabetes Mellitus**,** CRISPR-Cas9 Beta-Cell Editing**,** Insulin Therapy**,** GlycemiEc Control**,** Gene Editing Therapies.

INTRODUCTION

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by the selective destruction of insulin-producing pancreatic beta cells, resulting in absolute insulin deficiency and hyperglycemia [1, 2]. Globally, it affects approximately 9 million people, with onset commonly occurring in childhood or young adulthood [3]. Conventional management has centered on exogenous insulin administration to maintain euglycemia and prevent acute or chronic complications. Despite advances in insulin formulations, delivery devices, and continuous glucose monitoring, achieving optimal glycemic control remains elusive for many patients due to factors such as hypoglycemia risk, glucose variability, and the psychological burden of lifelong therapy.

Emerging genomic technologies, particularly CRISPR-Cas9 mediated genome editing, offer potential transformative interventions for T1DM [4, 5]. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) with Cas9 nuclease enables precise genomic modifications. Recent studies have explored its application in editing autologous stem cells or pancreatic progenitor cells to restore or regenerate functional beta cells capable of endogenous insulin production. Such an approach, if proven safe and effective, could offer durable remission or even a cure by addressing the underlying cellular deficit rather than merely managing hyperglycemia symptoms.

This narrative review critically examines the effectiveness of CRISPR-Cas9 beta-cell editing compared to traditional insulin therapy on glycemic control in adults with T1DM. It explores the mechanistic rationale, preclinical and early clinical evidence, therapeutic benefits, potential risks, and translational challenges. Understanding these comparative outcomes is crucial as the field progresses towards precision and regenerative therapies in diabetes management.

The review aims to inform clinicians, researchers, and policymakers on the promise and current limitations of gene-editing strategies vis-à-vis standard insulin replacement, facilitating evidence-based integration of innovative interventions in future clinical practice.

Pathophysiology of Type 1 Diabetes and Limitations of Insulin Therapy

Type 1 diabetes is driven by an autoimmune-mediated destruction of pancreatic beta cells, predominantly via CD4+ and CD8+ T lymphocytes recognizing beta-cell antigens such as insulin, GAD65, and IA-2 [6, 7]. The loss of beta-cell mass leads to a near-complete cessation of endogenous insulin secretion, necessitating lifelong exogenous insulin replacement. Although intensive insulin therapy using basal-bolus regimens or continuous subcutaneous insulin infusion (CSII) can approximate physiological insulin delivery, glycemic variability persists due to the absence of endogenous beta-cell function, hepatic first-pass insulin effects, and counter-regulatory hormonal responses.

Hypoglycemia, especially severe episodes requiring external assistance, remains a significant barrier to optimal glycemic targets [8, 9]. Additionally, chronic hyperglycemia contributes to microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular complications (cardiovascular disease). Insulin therapy also imposes a substantial psychosocial burden due to frequent glucose monitoring, dose adjustments, and the ever-present fear of hypoglycemia. These limitations highlight the need for novel disease-modifying treatments that can restore physiological insulin secretion and glucose homeostasis.

CRISPR-Cas9 Beta-Cell Editing: Mechanistic Rationale and Therapeutic Approaches

CRISPR-Cas9 gene editing offers unprecedented precision in modifying genomic sequences to correct disease-causing mutations or engineer therapeutic cellular functions [10]. Preclinical studies have demonstrated successful generation of insulin-secreting beta-like cells from CRISPR-edited iPSCs capable of reversing hyperglycemia in diabetic mice. These proof-of-concept studies form the foundation for future clinical translation in humans. In the context of T1DM, two main approaches are under investigation:

i. **Editing Autologous Stem or Progenitor Cells**: Patient-derived induced pluripotent stem cells (iPSCs) can be edited using CRISPR-Cas9 to promote differentiation into functional beta-like cells [11]. The edited cells can be encapsulated to prevent immune rejection and reintroduced to restore endogenous insulin secretion. This approach bypasses the need for lifelong immunosuppression associated with allogeneic islet transplantation.

ii. **Immune Evasion Strategies**: CRISPR-Cas9 can be used to knock out or modulate immune recognition molecules in stem cell-derived beta cells to confer resistance to autoimmune destruction [12]. For example, deletion of HLA class I molecules or overexpression of immune checkpoint molecules (PD-L1) can protect transplanted beta cells from cytotoxic T cell-mediated lysis.

Comparative Outcomes: CRISPR-Cas9 Beta-Cell Editing versus Insulin Therapy

i. Glycemic Control: Exogenous insulin administration, while effective in lowering blood glucose, does not replicate the dynamic glucose-responsive insulin secretion of native beta cells [13]. Glycemic variability and suboptimal postprandial glucose control persist despite intensive regimens. Continuous glucose monitoring studies show that less than 30% of T1DM patients achieve recommended HbA1c targets (<7%) without experiencing significant hypoglycemia. By restoring endogenous beta-cell function, CRISPR-edited beta-like cells can potentially achieve tighter glucose regulation with physiological insulin kinetics. Animal studies report near-normalization of blood glucose levels without hypoglycemia following transplantation of edited beta-like cells. However, human clinical trial data remain limited, with safety and long-term engraftment efficacy yet to be established.

ii. Risk of Hypoglycemia: Exogenous insulin's fixed absorption profiles increase the risk of hypoglycemia, particularly nocturnal hypoglycemia and hypoglycemia unawareness in long-standing T1DM patients [14]. Endogenous insulin secretion by edited beta cells is glucose-dependent, mimicking physiological feedback control, thereby reducing hypoglycemia risk. This advantage has been demonstrated in animal models but awaits confirmation in human subjects.

iii. Treatment Burden: Requires frequent glucose monitoring, dose adjustments, and imposes a significant lifestyle burden. If proven safe and durable, beta-cell editing could minimize or eliminate the need for daily insulin injections and glucose monitoring, significantly enhancing patient quality of life. However, preparatory procedures, potential immune conditioning, and transplant surgery carry their own risks.

iv. Long-Term Efficacy and Safety: Efficacy is maintained lifelong but does not modify disease progression or immune dysfunction. Chronic complications remain prevalent despite optimal therapy. Potentially disease-modifying by restoring endogenous insulin production [15]. Safety concerns include off-target genomic effects, tumorigenicity of stem cell-derived products, and immune rejection or recurrence of

autoimmunity. Strategies such as precise guide RNA design, rigorous off-target screening, and immune-evasion engineering are under development to mitigate these risks.

Ethical, Regulatory, and Translational Challenges

Regulatory frameworks by the FDA, EMA, and national agencies require stringent preclinical safety data, robust manufacturing standards, and phased clinical trials before approval [16]. First-in-human trials for CRISPR-based therapies are ongoing in other diseases (e.g. sickle cell disease), providing valuable insights into translational pathways for diabetes applications [17]. CRISPR-Cas9-based therapies for T1DM raise several ethical and regulatory issues:

i. **Genomic Integrity:** Ensuring no unintended genomic alterations that could predispose to malignancy [18].
ii. **Germline Editing Risks:** Strict protocols to prevent germline modifications when editing somatic stem cells.
iii. **Immune Responses:** Managing immunogenicity of edited cells and potential autoimmune recurrence [19].
iv. **Accessibility and Cost:** High manufacturing and regulatory costs could limit widespread adoption, raising health equity concerns.
v. **Long-Term Monitoring:** Necessity for lifelong surveillance for safety and efficacy outcomes.

Future Directions and Research Gaps

Key priorities for advancing CRISPR-Cas9 beta-cell editing in T1DM include:

i. **Optimization of Beta-Cell Differentiation Protocols:** Enhancing functional maturity and glucose-responsiveness of derived beta cells [20].
ii. **Immune-Evasion Engineering:** Developing universal donor beta cells resistant to both alloimmune and autoimmune attacks.
iii. **Minimizing Off-Target Effects:** Employing high-fidelity Cas9 variants and improved guide RNA design [21, 22].
iv. **Scalable Manufacturing:** Establishing Good Manufacturing Practice (GMP)-compliant production of edited cell therapy products.
v. **Clinical Trials:** Initiating well-designed Phase I/II trials to assess safety, engraftment, immune tolerance, and glycemic efficacy in humans.
vi. **Socioeconomic and Ethical Evaluations:** Assessing long-term cost-effectiveness, access models, and ethical acceptability among diverse patient populations.

CONCLUSION

CRISPR-Cas9 beta-cell editing represents a revolutionary advance in diabetes therapeutics, offering the possibility of disease modification or cure by restoring endogenous insulin production. Compared to traditional insulin therapy, gene-edited beta-cell interventions promise superior glycemic control, reduced hypoglycemia risk, and lower treatment burden by addressing the root cause of T1DM – beta-cell deficiency. However, the field remains in early translational stages, with most evidence derived from preclinical animal models. Major hurdles, including genomic safety, immune rejection, manufacturing scalability, and ethical considerations, must be addressed before routine clinical implementation. Insulin therapy, despite its limitations, remains the current gold standard with proven safety and effectiveness over decades.

Future success of CRISPR-Cas9 beta-cell editing will depend on collaborative efforts integrating basic science, bioengineering, clinical research, ethics, and health policy. If successfully translated, it could transform the management of T1DM, offering patients freedom from lifelong insulin dependence and significantly improving long-term health outcomes and quality of life.

REFERENCES

1. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat Prod Commun. 20, (2025). https://doi.org/10.1177/1934578X251323393
2. Ugwu, O.P.-C., Erisa, K., Raphael, I., Emmanuel I., O., Alum, E.U., Michael B, O., Subbarayan, S., Sankarapandiyan, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences. 12, 214–224 (2023). https://doi.org/10.59298/INOSRES/2023/2.17.1000
3. Green, A., Hede, S.M., Patterson, C.C., Wild, S.H., Imperatore, G., Roglic, G., Beran, D.: Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 64, 2741–2750 (2021). https://doi.org/10.1007/S00125-021-05571-8/FIGURES/3

4. Ikpozu EN, Offor CE, Igwenyi, I.O, Ibiam, U.A., Obaroh, I.O. et al. RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 2025;22(2). doi:10.1177/14791641251334726
5. Addissouky, T.A.: Beyond insulin: advancing frontiers in cell-based and genetic therapies for type 1 diabetes management. The Egyptian Journal of Internal Medicine 2025 37:1. 37, 1–17 (2025). https://doi.org/10.1186/S43162-025-00477-Y
6. Radenkovic, M. V: Cellular Immunological Mechanisms Contributing to Diabetes Pathogenesis. Faculty of Medicine Doctoral Dissertation Series. 2016, 111
7. Van Belle, T.L., Coppieters, K.T., Von Herrath, M.G.: Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev. 91, 79–118 (2011). https://doi.org/10.1152/PHYSREV.00003.2010/ASSET/IMAGES/LARGE/Z9J0011125670003.JPEG
8. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health* **22**, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
9. Aja, P. M., Umoru, G.U., Aja, P., Ugwu, O.P.-C., Orji, O.U., Nwali, B.U., Ezeani, N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect of Ethanol Leaf Extract of *Datura stramonium* in Alloxan-induced Diabetic Albino Rats. J. Chem. Soc. Nigeria. 47, 1165–1176 (2022). https://doi.org/10.46602/jcsn.v47i5.819
10. Zhang, M.L., Li, H. Bin, Jin, Y.: Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy. Front Genet. 15, 1364742 (2024). https://doi.org/10.3389/FGENE.2024.1364742/XML
11. Millette, K., Georgia, S.: Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development. Curr Diab Rep. 17, 1–10 (2017). https://doi.org/10.1007/S11892-017-0947-3/METRICS
12. Yang, K., Zhang, Y., Ding, J., Li, Z., Zhang, H., Zou, F.: Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection. Front Endocrinol (Lausanne). 15, 1377322 (2024). https://doi.org/10.3389/FENDO.2024.1377322/XML
13. Krishnamoorthy, R., Gatasheh, M. K., Subbarayan, S., Vijayalakshmi, P., Uti, D. E. Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Natural Product Communications. 2024;19(12). doi:10.1177/1934578X241299279
14. Hölzen, L., Schultes, B., Meyhöfer, S.M., Meyhöfer, S.: Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications. Biomedicines 2024, Vol. 12, Page 391. 12, 391 (2024). https://doi.org/10.3390/BIOMEDICINES12020391
15. Addissouky, T.A.: Beyond insulin: advancing frontiers in cell-based and genetic therapies for type 1 diabetes management. The Egyptian Journal of Internal Medicine 2025 37:1. 37, 1–17 (2025). https://doi.org/10.1186/S43162-025-00477-Y
16. Bode, G.: Regulatory Guidance: ICH, EMA, FDA. Drug Discovery and Evaluation: Methods in Clinical Pharmacology, Second Edition. 1085–1138 (2020). https://doi.org/10.1007/978-3-319-68864-0_58
17. Amato, P., Mikhalchenko, A., Mitalipov, S.: The case for germline gene correction: state of the science. Fertil Steril. 124, 22–29 (2025). https://doi.org/10.1016/J.FERTNSTERT.2025.04.039
18. Chakravarthi, B.V.S.K., Nepal, S., Varambally, S.: Genomic and Epigenomic Alterations in Cancer. Am J Pathol. 186, 1724–1735 (2016). https://doi.org/10.1016/J.AJPATH.2016.02.023
19. Schett, G., Müller, F., Taubmann, J., Mackensen, A., Wang, W., Furie, R.A., Gold, R., Haghikia, A., Merkel, P.A., Caricchio, R., D'Agostino, M.A., Locatelli, F., June, C.H., Mougiakakos, D.: Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 20, 531–544 (2024). https://doi.org/10.1038/S41584-024-01139-Z;SUBJMETA=4023,565,692,700;KWRD=RHEUMATOLOGY,THERAPEUTICS
20. Velazco-Cruz, L., Goedegebuure, M.M., Millman, J.R.: Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells. Front Bioeng Biotechnol. 8, 557823 (2020). https://doi.org/10.3389/FBIOE.2020.00786/BIBTEX
21. Manghwar, H., Li, B., Ding, X., Hussain, A., Lindsey, K., Zhang, X., Jin, S., Manghwar, H., Li, B., Ding, X., Hussain, A., Zhang, X., Jin, S., Lindsey, K.: CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects. Advanced Science. 7, 1902312 (2020). https://doi.org/10.1002/ADVS.201902312
22. Wu, J., Yin, H.: Engineering guide RNA to reduce the off-target effects of CRISPR. Journal of Genetics and Genomics. 46, 523–529 (2019). https://doi.org/10.1016/J.JGG.2019.11.003

Kintuza Lumwako Tebulo. Effect of CRISPR-Cas9 Beta-Cell Editing versus Insulin Therapy on Glycemic Control in Type 1 Diabetic Adults: A Narrative Review. EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES, 6(2):86-90.